Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Lesinurad/Allopurinol FDC
NCT02581553Phase 1Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Oct 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lesinurad + allopurinol in gout and hyperuricemia (6 arms), sponsored by Ardea Biosciences, Inc. Primary endpoints: Maximum Observed Concentration at Day 8, Time of Maximum Observed Concentration at Day 8 and 3 more. Started Oct 2015; status: completed.
02
Drugs
lesinurad + allopurinol
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02581553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581553.